Effects of Low-Dose and Long-Term Treatment with Erythromycin on Interleukin-17 and Interleukin-23 in Peripheral Blood and Induced Sputum in Patients with Stable Chronic Obstructive Pulmonary Disease
Table 2
The effect of erythromycin treatment on pulmonary function and 6-minute walk distance.
Parameter
Time
Placebo group
Group A
Group B
FEV1
Baseline
1.03 ± 0.25
1.05 ± 0.26
1.10 ± 0.26
Month 6
0.99 ± 0.26
1.14 ± 0.44
1.07 ± 0.27
Month 12
1.00 ± 0.26
1.11 ± 0.43
1.07 ± 0.28
FEV1 (% predicted)
Baseline
41.15 ± 11.46
45.64 ± 13.88
46.05 ± 8.96
Month 6
39.66 ± 9.14
48.26 ± 15.81
47.22 ± 9.62
Month 12
40.03 ± 8.50
48.58 ± 13.24
45.49 ± 9.09
FVC
Baseline
2.06 ± 0.29
2.38 ± 0.59
2.37 ± 0.44
Month 6
1.97 ± 0.40
2.43 ± 0.70
2.37 ± 0.50
Month 12
2.04 ± 0.39
2.41 ± 0.76
2.43 ± 0.53
FEV1/FVC
Baseline
49.74 ± 7.96
48.15 ± 7.74
47.38 ± 3.89
Month 6
50.56 ± 7.50
48.22 ± 8.11
46.63 ± 8.60
Month 12
49.29 ± 7.56
47.98 ± 8.45
44.91 ± 7.02
6MWD (m)
Baseline
345.09 ± 82.06
352.34 ± 69.05
347.45 ± 58.03
Month 6
326.37 ± 79.25
387.54 ± 62.35
389.43 ± 61.26
Month 12
304.86 ± 70.55
425.07 ± 32.84
352.80 ± 53.87
The mean ± standard deviation values are shown. Some pulmonary function indices including the forced expiratory volume in 1 second (FEV1), FEV1 (% predicted), FEV1/forced vital capacity (FVC), FVC, and the 6-minute walk distance (6MWD) are shown. Compared to the placebo treatment, value < .05; compared to baseline, value < .01.
